已发表论文

基于树突状细胞的疫苗治疗对高级别胶质瘤患者的疗效和安全性分析:一个系统评价和荟萃分析

 

Authors Li C, Liu T, Zhou B, Zhou Y, Yu H, Sun Y

Received 20 June 2018

Accepted for publication 13 September 2018

Published 24 October 2018 Volume 2018:11 Pages 7277—7293

DOI https://doi.org/10.2147/OTT.S177768

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 4

Editor who approved publication: Dr XuYu Yang

Background: Dendritic cell (DC)-based vaccine is a promising therapy for high-grade gliomas (HGGs); however, its actual effectiveness still remains controversial. This meta-analysis aims to extensively evaluate the efficacy and safety of DC vaccine for HGG patients.
Methods: We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and properly controlled non-randomized studies (NRS) published in English. Two investigators reviewed all the texts and extracted information regarding overall survival (OS), progression-free survival (PFS), and adverse events (AEs) from eligible studies. Sensitivity analyses and subgroup analyses were also conducted.
Results: Of 353 suitable studies, 13 studies (three RCTs and ten NRS) involving 944 patients were finally included. Compared to the control therapy group (CT group), the DC group showed better OS and PFS without serious AEs. Subgroup analysis showed that trials designed as NRS obtained better results in the DC group in this study; however, no specific subgroup regarding dosages, cycles or injection routes was found to be superior in the DC group compared to the CT group.
Conclusion: DC vaccine can significantly improve OS and PFS, with acceptable toxicity, of HGG patients. Nevertheless, further studies are needed to verify this conclusion.
Keywords: dendritic cell, vaccine, glioblastoma multiforme, high-grade gliomas, overall survival, progression-free survival




Figure 2 Risk of bias analysis for randomized clinical trials included.